Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Consolidated Net Income: 2017-2025

Historic Consolidated Net Income for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $8.8 million.

  • Puma Biotechnology's Consolidated Net Income fell 56.47% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year increase of 28.66%. This contributed to the annual value of $23.2 million for FY2024, which is 7.47% up from last year.
  • Per Puma Biotechnology's latest filing, its Consolidated Net Income stood at $8.8 million for Q3 2025, which was up 51.05% from $5.9 million recorded in Q2 2025.
  • Puma Biotechnology's Consolidated Net Income's 5-year high stood at $20.3 million during Q3 2024, with a 5-year trough of -$44.7 million in Q3 2021.
  • Its 3-year average for Consolidated Net Income is $5.7 million, with a median of $5.8 million in 2023.
  • As far as peak fluctuations go, Puma Biotechnology's Consolidated Net Income soared by 1,710.00% in 2023, and later tumbled by 443.68% in 2024.
  • Over the past 5 years, Puma Biotechnology's Consolidated Net Income (Quarterly) stood at $4.2 million in 2021, then crashed by 232.72% to -$5.6 million in 2022, then soared by 318.84% to $12.3 million in 2023, then decreased by 0.31% to $12.2 million in 2024, then crashed by 56.47% to $8.8 million in 2025.
  • Its Consolidated Net Income was $8.8 million in Q3 2025, compared to $5.9 million in Q2 2025 and $3.0 million in Q1 2025.